Skip to main content
| 07/03/2024

Dr. Peter Ganz Joins SeeMedX Advisory Board

Dr. Peter Ganz, a distinguished leader in cardiology and cardiac research pioneer, joins the advisory board at SeeMedX.

SeeMedX recently announced the appointment of Dr. Peter Ganz to our advisory board. Learn more about what this means for our company.  

Dr. Peter Ganz Joins SeeMedX Advisory Board

Dr. Ganz is a distinguished leader in cardiology, a pioneer in clinical cardiac research, and the newest member of the SeeMedX advisory board. SeeMedX is changing the way Congestive Heart Failure is treated with our state-of-the-art noninvasive cardiac monitoring technology, which can predict a cardiac event 48-72 hours before it happens.

“Dr. Ganz’s extensive expertise and experience will be instrumental in guiding SeeMedX as we advance our innovative cardiac monitoring solutions,” said SeeMedX CEO Deborah Simpson.

Dr. Ganz is the Director of the Center of Excellence in Vascular Research at the Zuckerberg San Francisco General Hospital and a Professor of Medicine at the University of California, San Francisco (“UCSF”). Dr. Ganz spent 25 years directing cardiovascular research in the Cardiac Catheterization Laboratories at the Brigham and Women’s Hospital and Harvard Medical School and served as the Chief of the Cardiovascular Division at Zuckerberg San Francisco General Hospital and the Maurice Eliaser Distinguished Professor of Medicine at UCSF. 

Dr. Ganz has published extensively in prestigious medical journals and has received numerous recognitions for his contributions to cardiology.

“Because of his standing in the cardiology community, his belief in the efficacy of SeeMedX’s non-invasive hemodynamic monitoring system will be influential with cardiologists around the world,” adds Simpson. 

A Non-Invasive Approach to Monitoring Congestive Heart Failure

Congestive Heart Failure (CHF) is a common disorder affecting an estimated 26 million people worldwide. CHF has a high morbidity and mortality rate and contributes to increased healthcare costs, reduces functional capacity, and significantly affects the quality of life for millions of patients. 

Diagnosing and effectively treating CHF is needed to prevent recurrent hospitalizations, decrease morbidity and mortality, and enhance patient outcomes. Unfortunately, most diagnoses and monitoring of CHF can be invasive and risky to patients. SeeMedX has developed a non-invasive monitoring device for CHF that can predict cardiac events up to 72 hours in advance.

“In today’s environment, doctors need access to technology like SeeMedX has developed,” said Dr. Ganz. “Their non-invasive hemodynamic monitor can provide much-needed information accurately, economically, safely, and rapidly. It has the potential to prevent hospitalizations for acute decompensated heart failure by diagnosing volume overload before it becomes clinically apparent. I look forward to working with them to establish the use of the technology as a clinical standard in cardiology practices.”

SeeMedX is dedicated to revolutionizing cardiac care by developing advanced cardiac monitoring systems utilizing bioimpedance technology. Our mission is to provide healthcare professionals with accurate, real-time data to improve patient outcomes. Learn  more about our technology at